Nanopath Raises $25M for 15-Minute Women's Health Tests

The patient visit is the unit Nanopath is designing around. Its molecular diagnostics platform is intended to put a useful answer in the room while clinician and patient are still together, a goal that reaches from biosensor design to the time available for a conversation. That ambition gives the financing behind Nanopath a specific destination.

The Cambridge, Massachusetts company announced $25M in Series B financing on November 10, 2026, including $2M in non-dilutive grants. Norwest and SV Health Investors' MedTech Convergence Fund co-led, with Labcorp Venture Fund, Elderberry Ventures, GingerBread Capital and Alumni Ventures participating. The funding supports manufacturing scale-up, a planned FDA 510(k) clinical study and team expansion for a 15-minute point-of-care vaginitis assay, according to the company announcement.

Nanopath is financing the work needed to bring an experimental diagnostic closer to clinical use. The commercial proposition is that a molecular result could become part of the appointment itself, giving a provider more information while the patient is present. Delivering on that proposition involves the test, the organization producing it and the evidence supporting its intended use.

A diagnostic designed for the appointment

Nanopath describes a cartridge-and-reader platform based on surface plasmon resonance, an optical biosensing technique. The design detects molecular targets without nucleic acid amplification, the copying step used in PCR. Its technology page presents speed, multiplexing and biosensor manufacturing as connected design priorities, with the platform intended for use at the point of care. These are company-described capabilities under development, with the specific vaginitis assay targeted at a 15-minute result. The company also states that its platform has yet to receive FDA clearance. Nanopath technology

For a clinic evaluating a future diagnostic, the result has to fit into work that is already happening. Sample collection, instrument operation and interpretation all belong to the same practical question of whether the information arrives in time to be useful during the visit. Nanopath's emphasis on a cartridge and reader makes that workflow part of the product proposition, alongside the sensing method.

The financing announcement places manufacturing and clinical work next to each other. That pairing is consequential for a physical diagnostic because a useful assay has to be produced consistently and studied for its intended setting. The round gives Nanopath resources to pursue those activities as it prepares for a potential launch. Specific pricing, a commercial launch date and comparative clinical performance were absent from the financing disclosure.

Founders who asked providers where to begin

Alison Burklund and Amogha Tadimety are Nanopath's co-founders and current co-CEOs. Their leadership team includes CMO Edward Evantash, CSO Matthew Black and VP of Engineering Matt Cote, bringing clinical, scientific and engineering responsibilities into the organization preparing the platform. The current company roster supplies the relevant titles as Nanopath enters this stage of development. Nanopath leadership

Burklund and Tadimety met at Dartmouth, where both earned engineering doctorates. In an August 2022 account of its investment, Norwest described the founders interviewing more than 100 healthcare providers through an NSF-supported customer discovery effort. Those conversations helped direct the company toward women's health. Norwest and SV Health Investors' MedTech Convergence Fund then co-led a $10M Series A, establishing an investment relationship that continues into the Series B. Norwest's founding and Series A account

That history helps explain the shape of the company being financed. A broad sensing technology creates choices about which clinical problem to address first, which users to understand and which product to build around their work. Provider discovery gave Nanopath a way to narrow those choices. Its current vaginitis program carries that decision forward into an assay with an intended time window and use setting.

For investors, returning to the company means funding a different stretch of the same undertaking. Earlier development established a technological direction. Manufacturing preparation, clinical execution and commercial hiring bring a wider set of responsibilities into the next phase, with more of the business organized around potential use in a clinic.

The support around a clinical-stage company

Nanopath's development has also drawn on the Massachusetts life-sciences ecosystem. The Massachusetts Life Sciences Center describes support through MassNextGen, internships and a 2026 tax incentive award. Its November 10 account reports more than $43K in MassNextGen funding and coaching, more than $52K supporting 10 interns since 2022, and a $288K tax incentive award tied to creating 12 jobs. Those programs show several forms of institutional involvement around the company as it grows. MLSC's support record

Support of that kind reaches into the people and capabilities a diagnostics developer needs over time. An internship program helps staff participate in the work, coaching gives founders access to experienced advice, and a hiring-related incentive attaches public support to planned employment. The Series B's inclusion of grant financing extends that mix of private and non-dilutive resources into the present announcement.

Nanopath is assembling several kinds of capacity around a tightly defined clinical goal. The science has to become a manufacturable system, the system has to be studied, and a team has to prepare for the responsibilities that would accompany commercialization. Each activity makes a claim on the same financing and on the founders' attention.

The 15-minute target gives those activities a shared purpose. As Burklund, Tadimety and their colleagues move toward the planned study, the eventual product proposition remains anchored in the appointment they hope to serve, with a molecular result available while the patient and clinician are still in the conversation.